カイダ　ケンイチ   KAIDA Kenichi   海田　賢一    所属   埼玉医科大学  医学部 総合医療センター　脳神経内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy
掲載誌名	正式名：Neurology: Neuroimmunology and NeuroInflammation ISSNコード：23327812
出版社	Lippincott Williams and Wilkins
巻・号・頁	3(6)
著者・共著者	Masato Kadoya,Ayumi Hida,Meiko Hashimoto Maeda,Kenichiro Taira,Chiseko Ikenaga,Naohiro Uchio,Akatsuki Kubota,Kenichi Kaida,Yusuke Miwa,Kazuhiro Kurasawa,Hiroyuki Shimada,Masahiro Sonoo,Atsuro Chiba,Yasushi Shiio,Yoshikazu Uesaka,Yasuhisa Sakurai,Toru Izumi,Manami Inoue,Shin Kwak,Shoji Tsuji,Jun Shimizu
発行年月	2016
概要	Objective: To show cancer association is a risk factor other than statin exposure for anti-3- hydroxy-3-methylglutaryl coenzyme A reductase autoantibody-positive (anti-HMGCR Ab1) myopathy. Methods: We analyzed the clinical features and courses of 33 patients (23 female and 10 male) with anti-HMGCR Ab1 myopathy among 621 consecutive patients with idiopathic inflammatory myopathies. Results: Among the 33 patients, 7 (21%) were statin-exposed and 26 were statin-naive. In relation with cancer, there were 12 patients (statin-exposed, n 5 4) with cancers detected within 3 years of myopathy diagnosis (cancer association), 3 patients (all statin-naive) with cancers detected more than 3 years before myopathy diagnosis (cancer history), 10 cancer-free patients followed up for more than 3 years (all statin-naive), and 8 patients without cancer detection but followed up for less than 3 years (statin-exposed, n 5 3). Therefore, 12 patients with cancer association (36%) formed a larger group than that of 7 statin-exposed patients (21%). Among 12 patients with cancer association, 92% had cancer detection within 1 year of myopathy diagnosis (after 1.3 years in the remaining patient), 83% had advan
DOI	10.1212/NXI.0000000000000290